Letter to the Editor: Indication-Specific Cost-Effectiveness of Empagliflozin Versus Dapagliflozin: Implications for Clinical and Policy Decision-Making
Abstract
Effectiveness of Empagliflozin and Dapagliflozin in ChinesePatients with Type 2 Diabetes Mellitus", which provides valuable real-world, head-to-head evidence comparing two widely used sodium-glucose cotransporter-2 (SGLT2) inhibitors.Using propensity score-matched retrospective data, the authors demonstrate largely comparable effects of empagliflozin and dapagliflozin on glycolipid metabolism, liver and kidney function in patients with type 2 diabetes mellitus (T2DM), with few clinically meaningful differences observed.1 Direct comparative effectiveness studies are highly important, particularly in the real-world setting.As the indications for SGLT2 inhibitors have expanded beyond T2DM to include heart failure (HF) and chronic kidney disease (CKD), and as long-term treatment is increasingly required, understanding not only comparisons in clinical effectiveness, but also relative economic value, has become essential for healthcare decision-making.Motivated by the findings of Zheng et al., I conducted a systematic literature review to evaluate and compare the cost-effectiveness and cost-utility evidence for empagliflozin versus dapagliflozin across their three main prescribing indications: T2DM, HF, and CKD.The review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.PubMed/MEDLINE was searched in December 2025 to identify studies published from 1 January 2020 onwards reporting cost-effectiveness…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.